Compassion Corner: Healthcare Workers Made Daily Visits to Cheer Lonely Patients, But Lawyers Questioned the Legality  
source: pixabay.com

 Compassion Corner: Healthcare Workers Made Daily Visits to Cheer Lonely Patients, But Lawyers Questioned the Legality  

Compassion [kuhm-pash-uhn] noun A feeling of deep sympathy and sorrow for another who is stricken by misfortune, accompanied by a strong desire to alleviate the suffering. Compassion Corner is a…

Continue Reading  Compassion Corner: Healthcare Workers Made Daily Visits to Cheer Lonely Patients, But Lawyers Questioned the Legality  
Innovations For Detecting Cancer Early
source: pixabay.com

Innovations For Detecting Cancer Early

According to a recent article, being able to detect cancer as soon as possible is vitally important as it allows time to administer curative treatments. Scientists are hopeful new treatments…

Continue Reading Innovations For Detecting Cancer Early

Chronic Lymphocytic Leukemia Patients Need Both Molecular And Clinical Risk Assessments

Dr. Deborah M. Stephens from the Huntsman Cancer Institute recently presented at the 39th Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow (CFS). The presentation surrounded how critical identifying…

Continue Reading Chronic Lymphocytic Leukemia Patients Need Both Molecular And Clinical Risk Assessments
New Collaboration to Evaluate Nirogacestat in Combination with ABBV-383 in Relapsed or Refractory Multiple Myeloma
https://unsplash.com/photos/tV-RX0beDp8

New Collaboration to Evaluate Nirogacestat in Combination with ABBV-383 in Relapsed or Refractory Multiple Myeloma

In a recent news release, biopharmaceutical companies AbbVie, Inc. and SpringWorks Therapeutics, Inc. ("SpringWorks") shared that the two had entered into a joint clinical trial collaboration agreement. Through this collaboration,…

Continue Reading New Collaboration to Evaluate Nirogacestat in Combination with ABBV-383 in Relapsed or Refractory Multiple Myeloma
First Subject Dosed in Laquinimod Trial for Uveitis
Source: https://unsplash.com/photos/6F2mPewg2RA

First Subject Dosed in Laquinimod Trial for Uveitis

On December 10, 2021, biotechnology company Active Biotech shared that the first subject was dosed within a Phase 1 clinical trial evaluating laquinimod for non-infectious non-anterior uveitis. What is particularly…

Continue Reading First Subject Dosed in Laquinimod Trial for Uveitis
AllStripes: How this HealthTech Company Leverages Science to Advance Rare Disease Research (Pt. 2)
AllStripes corporate lifestyle photo shoot at Salesforce park and AllStripes offices in San Francisco, Calif., Tuesday, Aug. 17, 2021. Photo by Alison Yin/Alison Yin Photography (Provided to PW by AllStripes)

AllStripes: How this HealthTech Company Leverages Science to Advance Rare Disease Research (Pt. 2)

Nancy Yu co-founded AllStripes with a vision in mind: to unlock more treatment options for those with rare diseases. In Part 1 of our interview, Patient Worthy sat down with…

Continue Reading AllStripes: How this HealthTech Company Leverages Science to Advance Rare Disease Research (Pt. 2)
Researchers Discover a Potential Treatment For Meningitis Without Using Antibiotics
source: pixabay.com

Researchers Discover a Potential Treatment For Meningitis Without Using Antibiotics

A recent article in Science Daily reports that researchers at the Copenhagen and Lund Universities, using animal models, killed bacterial meningitis without the use of antibiotics. Estimates from the WHO…

Continue Reading Researchers Discover a Potential Treatment For Meningitis Without Using Antibiotics
Phase 3 Trial For Topical Gene Therapy For Dystrophic Epidermolysis Bullosa Produces Positive Results
source: pixabay.com

Phase 3 Trial For Topical Gene Therapy For Dystrophic Epidermolysis Bullosa Produces Positive Results

Krystal Biotech has just announced results from their Phase 3 trial called GEM-3, and the results were all positive! This trial investigated bermemagene geperpavec (B-VEC), or VYJUVEKTM as a potential therapy…

Continue Reading Phase 3 Trial For Topical Gene Therapy For Dystrophic Epidermolysis Bullosa Produces Positive Results